Business Context and Reporting Period
Company: Contineum Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2025
Reporting Period: Event date December 11, 2025; Offering closed December 15, 2025.
Business Context: The Company, an emerging growth company incorporated in Delaware, entered into a material definitive agreement to conduct a public offering of its Class A common stock.
Key Financial Metrics
Offering Details:
- Shares Sold: 7,346,938 shares of Class A common stock.
- Public Offering Price: $12.25 per share.
- Underwriting Price: $11.515 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,102,040 additional shares.
- Estimated Net Proceeds: Approximately $84.2 million (excluding over-allotment exercise).
- Underwriters: Goldman Sachs & Co. LLC and Leerink Partners LLC.
Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report rather than a periodic financial statement.
Material Changes
Capital Structure Change: The Company significantly increased its equity capital through the sale of approximately 7.35 million shares. The offering was upsized from an initially proposed $75.0 million to a priced $90.0 million offering.
Liquidity Impact: The transaction is expected to provide approximately $84.2 million in net proceeds to the Company, substantially increasing available cash resources.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the pricing of the upsized offering via press release on December 11, 2025. The offering was conducted pursuant to a shelf registration statement (Form S-3) declared effective on May 23, 2025.
Risks and Contingencies: The Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The legal opinion regarding the legality of the issuance was provided by Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP. The filing notes that representations in the Underwriting Agreement were made solely for the benefit of the parties and may be subject to limitations.
Investor Verification Checklist
- Verify the final closing date of the offering (stated as December 15, 2025) and confirm receipt of net proceeds.
- Review the final prospectus supplement (dated December 11, 2025) for specific use of proceeds and risk factors.
- Monitor whether the underwriters exercise the 30-day over-allotment option for up to 1,102,040 additional shares.
- Confirm the impact of the offering on the Company's total share count and potential dilution to existing shareholders.
- Check subsequent filings for any updates on the Company's cash position or strategic deployment of the raised capital.